Moderna’s Early Coronavirus Vaccine Results Show It Can Spur An Immune Response
Early data on a possible COVID-19 vaccine show that it triggered an immune response in all 45 people tested, researchers announced Tuesday.
The preliminary results of the study, published in the New England Journal of Medicine, were cautiously viewed as significant step to quickly develop a vaccine for a virus that has shut down countries and economies around the globe and killed more than 576,000 so far, including more than 136,000 in the US.
The experimental drug, given in two doses, was developed by Cambridge, Massachusetts-based Moderna Therapeutics and the supported by the National Institutes of Health (NIH), which began safety testing on 45 subjects in March.
“No matter how you slice this, this is good news,” Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, a division of NIH, told The Associated Press.
The vaccine being developed by Moderna, mRNA-1273, is one of among more than 155 vaccines being tested and developed around the globe in hopes of curbing the worldwide pandemic, 23 of which are in human clinical trials.
Moderna is one of six companies that have received significant funding from the …continued .